FDA granted Priority Review for alectinib, an oral investigational anaplastic lymphoma kinase inhibitor, for the treatment of people with ALK-positive, locally advanced or metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
